DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Mapatumumab
Mapatumumab
Tanibirumab (CUI C3490677) Add to Cart
Highlights from the Pan Pacific Lymphoma Conference
The Two Tontti Tudiul Lui Hi Ha Unit
Monoclonal Antibody-Based Therapy As a New Treatment Strategy in Multiple Myeloma
Molecular Targeted Therapies for Indolent Lymphomas: Where Are
(INN) for Biological and Biotechnological Substances
Towards Novel Paradigms for Cancer Therapy
Targeted Therapy–Based Combination Treatment in Rhabdomyosarcoma Anke E.M
Anticancer Activity of the Type I Insulin-Like Growth Factor Receptor Antagonist, Ganitumab, in Combination with the Death Receptor 5 Agonist, Conatumumab
A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
The Integration of Biological Agents and Identification of New Targets
20 13 Rep Or T
To Kill a Tumor Cell: the Potential of Proapoptotic Receptor Agonists
(INN) for Biological and Biotechnological Substances
Death Receptor Agonists As a Targeted Therapy for Cancer
Curriculum Vitae and Bibliography a Keith Stewart, MB Chb, MBA
WO 2017/011544 Al 19 January 2017 (19.01.2017) P O PCT
Novel Antibodies in the Treatment of Non-Hodgkin's Lymphoma
Top View
Investigational Monoclonal Antibodies in the Treatment of Multiple Myeloma: a Systematic Review of Agents Under Clinical Development
The Impact of Induction Regimes on Immune Responses in Patients with Multiple Myeloma
A Tale of Two Trials for Abraxis and Human Genome Sciences Lung Cancer Data
Induction of Potent NK Cell-Dependent Anti-Myeloma Cytotoxic T Cells in Response to Combined Mapatumumab and Bortezomib
An Overview of the Current Status of Engineered Therapeutic Monoclonal Antibodies
Antibodies and Derivatives Targeting DR4 and DR5 for Cancer Therapy
Advances in Drug Development
Antibody Therapy of Cancer
Midostaurin Potentiates Rituximab Antitumor Activity in Burkitt’S
Phage Display Derived Monoclonal Antibodies: from Bench to Bedside
Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer
Advances in Phage Display Technology for Drug Discovery
Efficacy of Triple Therapies Including Ionising Radiation, Agonistic TRAIL Antibodies and Cisplatin
Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study Constantijne H
Hyperthermia Enhances Mapatumumab-Induced Apoptotic Death Through Ubiquitin-Mediated Degradation of Cellular FLIP(Long) in Human Colon Cancer Cells
Monoclonal Antibodies: an Emerging Class of Therapeutics in Non Small Cell Lung Cancer
HHS Public Access Author Manuscript
Activated B-Cell
Open Full Page
Antibody Phage Display Libraries: Contributions to Oncology
Protein-Polymer-Drug Conjugates Protein-Polymer-Wirkstoffkonjugate Conjugués De Médicament-Protéine-Polymère
(INN) for Biological and Biotechnological Substances
Ramesh Rengan, MD Ph.D. Radiation Therapy Contraindications And
New Strategies in the Treatment of Multiple Myeloma
Myeloma Update on Treatment and Side Effects Management
Exploring a Therapeutic Role for IGF1R Inhibitors in Triple-Negative Breast Cancer Onyinye Offor
Synergistic Induction of Apoptosis by Mapatumumab and Anthracyclines in Human Bladder Cancer Cells
Therapeutics Targeting the Core Apoptotic Machinery
Supplementary Tables and Figures
On the TRAIL to Successful Cancer Therapy? Predicting and Counteracting Resistance Against TRAIL-Based Therapeutics